


What is claimed is:

1. A compound of formula Ia:



(Ia)

- 5 or a pharmaceutically acceptable salt or hydrate thereof, wherein:

$R_1$  is  $\text{CO}_2R_4$ ;

- each  $R_2$  is independently -halo,  $-\text{NO}_2$ ,  $-\text{CN}$ ,  $-\text{OH}$ ,  $-\text{N}(\text{R}_5)(\text{R}_5)$ ,  $-\text{OR}_5$ ,  $-\text{C}(\text{O})\text{R}_5$ ,  $-\text{OC}(\text{O})\text{R}_5$ ,  $-\text{C}(\text{O})\text{NHC}(\text{O})\text{R}_5$ ,  $-(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-(\text{C}_2-\text{C}_{10})\text{alkenyl}$ ,  $-(\text{C}_2-\text{C}_{10})\text{alkynyl}$ ,  $-(\text{C}_3-\text{C}_{10})\text{cycloalkyl}$ ,  $-(\text{C}_8-\text{C}_{14})\text{bicycloalkyl}$ ,  $-(\text{C}_5-\text{C}_{10})\text{cycloalkenyl}$ ,  $-(\text{C}_3-\text{C}_{10})\text{heterocycle}$ ,   
 10 -phenyl, -naphthyl, -benzyl,  $-\text{CO}_2\text{R}_5$ ,  $-\text{C}(\text{O})\text{OCH}(\text{R}_5)(\text{R}_5)$ ,  $-\text{NHC}(\text{O})\text{R}_5$ ,  $-\text{NHC}(\text{O})\text{NHR}_5$ ,  $-\text{C}(\text{O})\text{NHR}_5$ ,  $-\text{OC}(\text{O})\text{R}_5$ ,  $-\text{OC}(\text{O})\text{OR}_5$ ,  $-\text{SR}_5$ ,  $-\text{S}(\text{O})\text{R}_5$ , or  $-\text{S}(\text{O})_2\text{R}_5$ ;

- $R_3$  is  $-\text{H}$ , -halo,  $-\text{NO}_2$ ,  $-\text{CN}$ ,  $-\text{OH}$ ,  $-\text{N}(\text{R}_5)(\text{R}_5)$ ,  $-\text{O}(\text{CH}_2)_m\text{R}_5$ ,  $-\text{C}(\text{O})\text{R}_5$ ,  $-\text{C}(\text{O})\text{NR}_5\text{R}_5$ ,  $-\text{C}(\text{O})\text{NH}(\text{CH}_2)_m(\text{R}_5)$ ,  $-\text{OCF}_3$ , -benzyl,  $-\text{CO}_2\text{CH}(\text{R}_5)(\text{R}_5)$ ,  $-(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-(\text{C}_2-\text{C}_{10})\text{alkenyl}$ ,  $-(\text{C}_2-\text{C}_{10})\text{alkynyl}$ ,  $-(\text{C}_3-\text{C}_{10})\text{cycloalkyl}$ ,  $-(\text{C}_8-\text{C}_{14})\text{bicycloalkyl}$ ,   
 15  $-(\text{C}_5-\text{C}_{10})\text{cycloalkenyl}$ , -naphthyl,  $-(\text{C}_3-\text{C}_{10})\text{heterocycle}$ ,  $-\text{CO}_2(\text{CH}_2)_m\text{R}_5$ ,  $-\text{NHC}(\text{O})\text{R}_5$ ,  $-\text{N}(\text{R}_5)\text{C}(\text{O})\text{R}_5$ ,  $-\text{NHC}(\text{O})\text{NHR}_5$ ,  $-\text{OC}(\text{O})(\text{CH}_2)_m\text{CHR}_5\text{R}_5$ ,  $-\text{CO}_2(\text{CH}_2)_m\text{CHR}_5\text{R}_5$ ,  $-\text{OC}(\text{O})\text{OR}_5$ ,  $-\text{SR}_5$ ,  $-\text{S}(\text{O})\text{R}_5$ ,  $-\text{S}(\text{O})_2\text{R}_5$ ,  $-\text{S}(\text{O})_2\text{NHR}_5$ , or



$R_4$  is  $-(\text{C}_5)\text{heteroaryl}$ ,  $-(\text{C}_6)\text{heteroaryl}$ , phenyl, naphthyl, or benzyl;

- 20 each  $R_5$  is independently  $-\text{H}$ ,  $-\text{CF}_3$ ,  $-(\text{C}_1-\text{C}_{10})\text{alkyl}$ , -benzyl, -adamantyl, -morpholinyl, -pyrrolidyl, -pyrroldioxide, -pyrrolidinylidone, -piperidyl,  $-(\text{C}_2-\text{C}_{10})\text{alkenyl}$ ,  $-(\text{C}_2-\text{C}_{10})\text{alkynyl}$ ,  $-(\text{C}_3-\text{C}_{10})\text{cycloalkyl}$ ,  $-(\text{C}_8-\text{C}_{14})\text{bicycloalkyl}$ ,  $-(\text{C}_3-\text{C}_{10})\text{heterocycle}$ , or



each  $R_6$  is independently  $-\text{H}$ , -halo,  $-\text{NO}_2$ ,  $-\text{CN}$ ,  $-\text{OH}$ ,  $-\text{CO}_2\text{H}$ ,

- 25  $-\text{N}((\text{C}_1-\text{C}_{10})\text{alkyl})(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-\text{O}(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-\text{C}(\text{O})(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-\text{C}(\text{O})\text{NH}(\text{CH}_2)_m(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-\text{OCF}_3$ , -benzyl,  $-\text{CO}_2(\text{CH}_2)_m\text{CH}((\text{C}_1-\text{C}_{10})\text{alkyl})(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-\text{C}(\text{O})\text{H}$ ,

-CO<sub>2</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, -phenyl, naphthyl, -(C<sub>3</sub>-C<sub>10</sub>)heterocycle, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>H, -NHC(O)(C<sub>1</sub>-C<sub>10</sub>)alkyl, -NHC(O)NH(C<sub>1</sub>-C<sub>10</sub>)alkyl, -OC(O)(C<sub>1</sub>-C<sub>10</sub>)alkyl, -OC(O)O(C<sub>1</sub>-C<sub>10</sub>)alkyl, -SO<sub>2</sub>NHR<sub>5</sub>, or -SO<sub>2</sub>NH<sub>2</sub>;


n is an integer ranging from 0 to 4;

each m is independently an integer ranging from 0 to 8; and

each p is independently an integer ranging from 0 to 5.

2. A pharmaceutical composition comprising an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or excipient.

3. A method for treating an inflammation disease in an animal, comprising administering to an animal in need thereof an effective amount of a compound of formula (Ic):




(Ic)

or a pharmaceutically acceptable salt or hydrate thereof, wherein:


R<sub>1</sub> is -H, -CO<sub>2</sub>R<sub>4</sub>; -C(O)R<sub>5</sub>, or -C(O)N(R<sub>5</sub>)(R<sub>5</sub>);

each R<sub>2</sub> is independently -halo, -NO<sub>2</sub>, -CN, -OH, -N(R<sub>5</sub>)(R<sub>5</sub>), -OR<sub>5</sub>, -C(O)R<sub>5</sub>, -C(O)NHC(O)(R<sub>5</sub>), -OC(O)R<sub>5</sub>, -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>3</sub>-C<sub>7</sub>)heterocycle, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, phenyl, -naphthyl, -benzyl, -CO<sub>2</sub>R<sub>5</sub>, -C(O)OCH(R<sub>5</sub>)(R<sub>5</sub>), -NHC(O)R<sub>5</sub>, -NHC(O)NHR<sub>5</sub>, -C(O)NHR<sub>5</sub>, -OC(O)R<sub>5</sub>, -OC(O)OR<sub>5</sub>, -SR<sub>5</sub>, -S(O)R<sub>5</sub>, or -S(O)<sub>2</sub>R<sub>5</sub>;

R<sub>3</sub> is -H, -halo, -NO<sub>2</sub>, -CN, -OH, -N(R<sub>5</sub>)(R<sub>5</sub>), -O(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>, -C(O)R<sub>5</sub>, -C(O)NR<sub>5</sub>R<sub>5</sub>, -C(O)NH(CH<sub>2</sub>)<sub>m</sub>(R<sub>5</sub>), -OCF<sub>3</sub>, -benzyl, -CO<sub>2</sub>CH(R<sub>5</sub>)(R<sub>5</sub>), -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, -naphthyl, -(C<sub>3</sub>-C<sub>10</sub>)heterocycle, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>, -NHC(O)R<sub>5</sub>, -NHC(O)R<sub>5</sub>, -NHC(O)NHR<sub>5</sub>, -OC(O)(CH<sub>2</sub>)<sub>m</sub>CHR<sub>5</sub>R<sub>5</sub>, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>CHR<sub>5</sub>R<sub>5</sub>, -OC(O)OR<sub>5</sub>, -SR<sub>5</sub>, -S(O)R<sub>5</sub>, -S(O)<sub>2</sub>R<sub>5</sub>, -S(O)<sub>2</sub>NHR<sub>5</sub>, or



- 5  $R_4$  is  $-CF_3$ ,  $-(C_1-C_{10})$ alkyl,  $-benzyl$ ,  $-adamantyl$ ,  $-morpholinyl$ ,  $-pyrrolidyl$ ,  $-pyrroldioxide$ ,  $-pyrrolidinyldione$ ,  $-piperidyl$ ,  $-(C_5)$ heteroaryl,  $-(C_6)$ heteroaryl,  $-(C_2-C_{10})$ alkenyl,  $-(C_2-C_{10})$ alkynyl,  $-(C_3-C_{10})$ cycloalkyl,  $-(C_8-C_{14})$ bicycloalkyl,  $-(C_3-C_{10})$ heterocycle, or




- 10 each  $R_5$  is independently H or  $R_4$ ;  
 each  $R_6$  is independently  $-halo$ ,  $-NO_2$ ,  $-CN$ ,  $-OH$ ,  $-CO_2H$ ,  $-N(C_1-C_{10})$ alkyl,  $-(C_1-C_{10})$ alkyl,  $-O(C_1-C_{10})$ alkyl,  $-C(O)(C_1-C_{10})$ alkyl,  $-C(O)NH(CH_2)_m(C_1-C_{10})$ alkyl,  $-OCF_3$ ,  $-benzyl$ ,  $-CO_2(CH_2)_mCH((C_1-C_{10})alkyl(C_1-C_{10})alkyl)$ ,  $-C(O)H$ ,  $-CO_2(C_1-C_{10})$ alkyl,  $-(C_1-C_{10})$ alkyl,  $-(C_2-C_{10})$ alkenyl,  $-(C_2-C_{10})$ alkynyl,  $-(C_3-C_{10})$ cycloalkyl,  
 15  $-(C_8-C_{14})$ bicycloalkyl,  $-(C_5-C_{10})$ cycloalkenyl,  $-(C_5)$ heteroaryl,  $-(C_6)$ heteroaryl,  $-phenyl$ ,  $-naphthyl$ ,  $-(C_3-C_{10})$ heterocycle,  $-CO_2(CH_2)_m(C_1-C_{10})$ alkyl,  $-CO_2(CH_2)_mH$ ,  $-NHC(O)(C_1-C_{10})$ alkyl,  $-NHC(O)NH(C_1-C_{10})$ alkyl,  $-OC(O)(C_1-C_{10})$ alkyl,  $-OC(O)O(C_1-C_{10})$ alkyl, or  $-SO_2NH_2$ ;  
 $n$  is an integer ranging from 0 to 4;  
 20 each  $m$  is independently an integer ranging from 0 to 8; and  
 each  $p$  is independently an integer ranging from 0 to 5.

4. The method of claim 3, wherein the inflammation disease is arthritis, psoriasis, gingivitis, colitis, uveitis, diabetes, adult respiratory distress syndrome,  
 25 autoimmune disease, lupus erythematosus, ileitis, ulcerative colitis, Crohn's disease, asthma, periodontitis, ophthalmitis, endophthalmitis, nephrosis, AIDS-related neurodegeneration, stroke, neurotrauma, Alzheimer's disease, encephalomyelitis, cardiomyopathy, or transplant rejection.

- 30 5. A method for treating a reperfusion disease in an animal, comprising administering to an animal in need thereof an effective amount of a compound of formula (Ic):

35



(Ic)

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

$R_1$  is -H,  $-\text{CO}_2R_4$ ;  $-\text{C}(\text{O})R_5$ , or  $-\text{C}(\text{O})\text{N}(\text{R}_5)(\text{R}_5)$ ;


5 each  $R_2$  is independently -halo,  $-\text{NO}_2$ ,  $-\text{CN}$ ,  $-\text{OH}$ ,  $-\text{N}(\text{R}_5)(\text{R}_5)$ ,  $-\text{OR}_5$ ,  $-\text{C}(\text{O})R_5$ ,  $-\text{OC}(\text{O})R_5$ ,  $-\text{C}(\text{O})\text{NHC}(\text{O})R_5$ ,  $-(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-(\text{C}_2-\text{C}_{10})\text{alkenyl}$ ,  $-(\text{C}_2-\text{C}_{10})\text{alkynyl}$ ,  $-(\text{C}_3-\text{C}_{10})\text{cycloalkyl}$ ,  $-(\text{C}_8-\text{C}_{14})\text{bicycloalkyl}$ ,  $-(\text{C}_5-\text{C}_{10})\text{cycloalkenyl}$ ,  $-(\text{C}_3-\text{C}_7)\text{heterocycle}$ ,  $-(\text{C}_5)\text{heteroaryl}$ ,  $-(\text{C}_6)\text{heteroaryl}$ , phenyl, -naphthyl, -benzyl,  $-\text{CO}_2R_5$ ,  $-\text{C}(\text{O})\text{OCH}(\text{R}_5)(\text{R}_5)$ ,  $-\text{NHC}(\text{O})R_5$ ,  $-\text{NHC}(\text{O})\text{NHR}_5$ ,  $-\text{C}(\text{O})\text{NHR}_5$ ,  $-\text{OC}(\text{O})R_5$ ,  $-\text{OC}(\text{O})\text{OR}_5$ ,  $-\text{SR}_5$ ,  $-\text{S}(\text{O})R_5$ , or

10  $-\text{S}(\text{O})_2R_5$ ;

$R_3$  is -H, -halo,  $-\text{NO}_2$ ,  $-\text{CN}$ ,  $-\text{OH}$ ,  $-\text{N}(\text{R}_5)(\text{R}_5)$ ,  $-\text{O}(\text{CH}_2)_mR_5$ ,  $-\text{C}(\text{O})R_5$ ,


$-\text{C}(\text{O})\text{NR}_5R_5$ ,  $-\text{C}(\text{O})\text{NH}(\text{CH}_2)_m(\text{R}_5)$ ,  $-\text{OCF}_3$ , -benzyl,  $-\text{CO}_2\text{CH}(\text{R}_5)(\text{R}_5)$ ,  $-(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-(\text{C}_2-\text{C}_{10})\text{alkenyl}$ ,  $-(\text{C}_2-\text{C}_{10})\text{alkynyl}$ ,  $-(\text{C}_3-\text{C}_{10})\text{cycloalkyl}$ ,  $-(\text{C}_8-\text{C}_{14})\text{bicycloalkyl}$ ,  $-(\text{C}_5-\text{C}_{10})\text{cycloalkenyl}$ ,  $-(\text{C}_5)\text{heteroaryl}$ ,  $-(\text{C}_6)\text{heteroaryl}$ , -naphthyl,  $-(\text{C}_3-\text{C}_{10})\text{heterocycle}$ ,  $-\text{CO}_2(\text{CH}_2)_mR_5$ ,  $-\text{NHC}(\text{O})R_5$ ,  $-\text{NHC}(\text{O})R_5$ ,  $-\text{NHC}(\text{O})\text{NHR}_5$ ,  $-\text{OC}(\text{O})(\text{CH}_2)_m\text{CHR}_5R_5$ ,  $-\text{CO}_2(\text{CH}_2)_m\text{CHR}_5R_5$ ,  $-\text{OC}(\text{O})\text{OR}_5$ ,  $-\text{SR}_5$ ,  $-\text{S}(\text{O})R_5$ ,  $-\text{S}(\text{O})_2R_5$ ,  $-\text{S}(\text{O})_2\text{NHR}_5$ , or

15



$R_4$  is  $-\text{CF}_3$ ,  $-(\text{C}_1-\text{C}_{10})\text{alkyl}$ , -benzyl, -adamantyl, -morpholinyl, -pyrrolidyl,

20 -pyrroldyloxide, -pyrrolidinyldione, -piperidyl,  $-(\text{C}_5)\text{heteroaryl}$ ,  $-(\text{C}_6)\text{heteroaryl}$ ,  $-(\text{C}_2-\text{C}_{10})\text{alkenyl}$ ,  $-(\text{C}_2-\text{C}_{10})\text{alkynyl}$ ,  $-(\text{C}_3-\text{C}_{10})\text{cycloalkyl}$ ,  $-(\text{C}_8-\text{C}_{14})\text{bicycloalkyl}$ ,  $-(\text{C}_3-\text{C}_{10})\text{heterocycle}$ , or



25

each  $R_5$  is independently H or  $R_4$ ;

each  $R_6$  is independently -halo,  $-\text{NO}_2$ ,  $-\text{CN}$ ,  $-\text{OH}$ ,  $-\text{CO}_2\text{H}$ ,  $-\text{N}(\text{C}_1-$

$\text{C}_{10})\text{alkyl}(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-\text{O}(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-\text{C}(\text{O})(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-\text{C}(\text{O})\text{NH}(\text{CH}_2)_m(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-\text{OCF}_3$ , -benzyl,  $-\text{CO}_2(\text{CH}_2)_m\text{CH}((\text{C}_1-\text{C}_{10})\text{alkyl}(\text{C}_1-\text{C}_{10})\text{alkyl})$ ,  $-\text{C}(\text{O})\text{H}$ ,  $-\text{CO}_2(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-(\text{C}_2-\text{C}_{10})\text{alkenyl}$ ,  $-(\text{C}_2-\text{C}_{10})\text{alkynyl}$ ,  $-(\text{C}_3-\text{C}_{10})\text{cycloalkyl}$ ,  $-(\text{C}_8-\text{C}_{14})\text{bicycloalkyl}$ ,  $-(\text{C}_5-\text{C}_{10})\text{cycloalkenyl}$ ,  $-(\text{C}_5)\text{heteroaryl}$ ,  $-(\text{C}_6)\text{heteroaryl}$ , -phenyl, -naphthyl,  $-(\text{C}_3-\text{C}_{10})\text{heterocycle}$ ,  $-\text{CO}_2(\text{CH}_2)_m(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-\text{CO}_2(\text{CH}_2)_m\text{H}$ ,  $-\text{NHC}(\text{O})(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-\text{NHC}(\text{O})\text{NH}(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-\text{OC}(\text{O})(\text{C}_1-\text{C}_{10})\text{alkyl}$ ,  $-\text{OC}(\text{O})\text{O}(\text{C}_1-\text{C}_{10})\text{alkyl}$ , or  $-\text{SO}_2\text{NH}_2$ ;

30

$n$  is an integer ranging from 0 to 4;

35


each  $m$  is independently an integer ranging from 0 to 8; and

each p is independently an integer ranging from 0 to 5.

6. The method of claim 5, wherein the reperfusion disease is hemorrhagic shock, sepsis, septic shock, myocardial infarction, or stroke.

5

7. A method for inhibiting xanthine oxidase activity in an animal, comprising administering to an animal in need thereof an effective amount of a compound of formula (Ic):



10


(Ic)

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

R<sub>1</sub> is -H, -CO<sub>2</sub>R<sub>4</sub>; -C(O)R<sub>5</sub>, or -C(O)N(R<sub>5</sub>)(R<sub>5</sub>);

each R<sub>2</sub> is independently -halo, -NO<sub>2</sub>, -CN, -OH, -N(R<sub>5</sub>)(R<sub>5</sub>), -OR<sub>5</sub>, -C(O)R<sub>5</sub>, -OC(O)R<sub>5</sub>, -C(O)NHC(O)R<sub>5</sub>, -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, 15 -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>3</sub>-C<sub>7</sub>)heterocycle, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, phenyl, -naphthyl, -benzyl, -CO<sub>2</sub>R<sub>5</sub>, -C(O)OCH(R<sub>5</sub>)(R<sub>5</sub>), -NHC(O)R<sub>5</sub>, -NHC(O)NHR<sub>5</sub>, -C(O)NHR<sub>5</sub>, -OC(O)R<sub>5</sub>, -OC(O)OR<sub>5</sub>, -SR<sub>5</sub>, -S(O)R<sub>5</sub>, or -S(O)<sub>2</sub>R<sub>5</sub>;

R<sub>3</sub> is -H, -halo, -NO<sub>2</sub>, -CN, -OH, -N(R<sub>5</sub>)(R<sub>5</sub>), -O(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>, -C(O)R<sub>5</sub>, 20 -C(O)NR<sub>5</sub>R<sub>5</sub>, -C(O)NH(CH<sub>2</sub>)<sub>m</sub>(R<sub>5</sub>), -OCF<sub>3</sub>, -benzyl, -CO<sub>2</sub>CH(R<sub>5</sub>)(R<sub>5</sub>), -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, -naphthyl, -(C<sub>3</sub>-C<sub>10</sub>)heterocycle, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>, -NHC(O)R<sub>5</sub>, -NHC(O)R<sub>5</sub>, -NHC(O)NHR<sub>5</sub>, -OC(O)(CH<sub>2</sub>)<sub>m</sub>CHR<sub>5</sub>R<sub>5</sub>, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>CHR<sub>5</sub>R<sub>5</sub>, -OC(O)OR<sub>5</sub>, -SR<sub>5</sub>, -S(O)R<sub>5</sub>, -S(O)<sub>2</sub>R<sub>5</sub>, -S(O)<sub>2</sub>NHR<sub>5</sub>, or



25

R<sub>4</sub> is -CF<sub>3</sub>, -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -benzyl, -adamantyl, -morpholinyl, -pyrrolidyl, -pyrroldyloxide, -pyrrolidinylidone, -piperidyl, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>3</sub>-C<sub>10</sub>)heterocycle, or



each R<sub>5</sub> is independently H or R<sub>4</sub>;


each  $R_6$  is independently -halo, -NO<sub>2</sub>, -CN, -OH, -CO<sub>2</sub>H, -N(C<sub>1</sub>-C<sub>10</sub>)alkyl(C<sub>1</sub>-C<sub>10</sub>)alkyl, -O(C<sub>1</sub>-C<sub>10</sub>)alkyl, -C(O)(C<sub>1</sub>-C<sub>10</sub>)alkyl, -C(O)NH(CH<sub>2</sub>)<sub>m</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl, -OCF<sub>3</sub>, -benzyl, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>CH((C<sub>1</sub>-C<sub>10</sub>)alkyl(C<sub>1</sub>-C<sub>10</sub>)alkyl), -C(O)H, -CO<sub>2</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, -phenyl, naphthyl, -(C<sub>3</sub>-C<sub>10</sub>)heterocycle, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>H, -NHC(O)(C<sub>1</sub>-C<sub>10</sub>)alkyl, -NHC(O)NH(C<sub>1</sub>-C<sub>10</sub>)alkyl, -OC(O)(C<sub>1</sub>-C<sub>10</sub>)alkyl, -OC(O)O(C<sub>1</sub>-C<sub>10</sub>)alkyl, or -SO<sub>2</sub>NH<sub>2</sub>;

$n$  is an integer ranging from 0 to 4;

each  $m$  is independently an integer ranging from 0 to 8; and

each  $p$  is independently an integer ranging from 0 to 5.

8. A method for treating hyperuricemia in an animal, comprising administering to an animal in need thereof an effective amount of a compound of formula (Ic):




(Ic)

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

$R_1$  is -H, -CO<sub>2</sub>R<sub>4</sub>, -C(O)R<sub>5</sub>, or -C(O)N(R<sub>5</sub>)(R<sub>5</sub>);

each  $R_2$  is independently -halo, -NO<sub>2</sub>, -CN, -OH, -N(R<sub>5</sub>)(R<sub>5</sub>), -OR<sub>5</sub>, -C(O)R<sub>5</sub>, -OC(O)R<sub>5</sub>, -C(O)NHC(O)R<sub>5</sub>, -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>3</sub>-C<sub>7</sub>)heterocycle, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, phenyl, -naphthyl, -benzyl, -CO<sub>2</sub>R<sub>5</sub>, -C(O)OCH(R<sub>5</sub>)(R<sub>5</sub>), -NHC(O)R<sub>5</sub>, -NHC(O)NHR<sub>5</sub>, -C(O)NHR<sub>5</sub>, -OC(O)R<sub>5</sub>, -OC(O)OR<sub>5</sub>, -SR<sub>5</sub>, -S(O)R<sub>5</sub>, or -S(O)<sub>2</sub>R<sub>5</sub>;

$R_3$  is -H, -halo, -NO<sub>2</sub>, -CN, -OH, -N(R<sub>5</sub>)(R<sub>5</sub>), -O(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>, -C(O)R<sub>5</sub>, -C(O)NR<sub>5</sub>R<sub>5</sub>, -C(O)NH(CH<sub>2</sub>)<sub>m</sub>(R<sub>5</sub>), -OCF<sub>3</sub>, -benzyl, -CO<sub>2</sub>CH(R<sub>5</sub>)(R<sub>5</sub>), -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, -naphthyl, -(C<sub>3</sub>-C<sub>10</sub>)heterocycle, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>, -NHC(O)R<sub>5</sub>, -NHC(O)R<sub>5</sub>, -NHC(O)NHR<sub>5</sub>, -OC(O)(CH<sub>2</sub>)<sub>m</sub>CHR<sub>5</sub>R<sub>5</sub>, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>CHR<sub>5</sub>R<sub>5</sub>, -OC(O)OR<sub>5</sub>, -SR<sub>5</sub>, -S(O)R<sub>5</sub>, -S(O)<sub>2</sub>R<sub>5</sub>, -S(O)<sub>2</sub>NHR<sub>5</sub>, or



$R_4$  is -CF<sub>3</sub>, -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -benzyl, -adamantyl, -morpholinyl, -pyrrolidyl, -pyrroldioxide, -pyrrolidinylidone, -piperidyl, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl,

-(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl,  
-(C<sub>3</sub>-C<sub>10</sub>)heterocycle, or




5

each R<sub>5</sub> is independently H or R<sub>4</sub>;

each R<sub>6</sub> is independently -halo, -NO<sub>2</sub>, -CN, -OH, -CO<sub>2</sub>H, -N(C<sub>1</sub>-  
C<sub>10</sub>)alkyl(C<sub>1</sub>-C<sub>10</sub>)alkyl, -O(C<sub>1</sub>-C<sub>10</sub>)alkyl, -C(O)(C<sub>1</sub>-C<sub>10</sub>)alkyl, -C(O)NH(CH<sub>2</sub>)<sub>m</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl,  
-OCF<sub>3</sub>, -benzyl, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>CH((C<sub>1</sub>-C<sub>10</sub>)alkyl(C<sub>1</sub>-C<sub>10</sub>)alkyl), -C(O)H, -CO<sub>2</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl,  
10 -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-  
C<sub>14</sub>)bicycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, -phenyl, naphthyl,  
-(C<sub>3</sub>-C<sub>10</sub>)heterocycle, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>H, -NHC(O)(C<sub>1</sub>-C<sub>10</sub>)alkyl,  
-NHC(O)NH(C<sub>1</sub>-C<sub>10</sub>)alkyl, -OC(O)(C<sub>1</sub>-C<sub>10</sub>)alkyl, -OC(O)O(C<sub>1</sub>-C<sub>10</sub>)alkyl, or -SO<sub>2</sub>NH<sub>2</sub>;  
n is an integer ranging from 0 to 4;  
15 each m is independently an integer ranging from 0 to 8; and  
each p is independently an integer ranging from 0 to 5.

9. The method of claim 8, wherein the hyperuricemia is gout.

20 10. A method for treating tumor-lysis syndrome in an animal, comprising  
administering to an animal in need thereof an effective amount of a compound of formula  
(Ic):



(Ic)


25 or a pharmaceutically acceptable salt or hydrate thereof, wherein:

R<sub>1</sub> is -H, -CO<sub>2</sub>R<sub>4</sub>, -C(O)R<sub>5</sub>, or -C(O)N(R<sub>5</sub>)(R<sub>5</sub>);

each R<sub>2</sub> is independently -halo, -NO<sub>2</sub>, -CN, -OH, -N(R<sub>5</sub>)(R<sub>5</sub>), -OR<sub>5</sub>, -C(O)R<sub>5</sub>,  
-OC(O)R<sub>5</sub>, -C(O)NHC(O)R<sub>5</sub>, -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl,  
-(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>3</sub>-C<sub>7</sub>)heterocycle,  
30 -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, phenyl, -naphthyl, -benzyl, -CO<sub>2</sub>R<sub>5</sub>, -C(O)OCH(R<sub>5</sub>)(R<sub>5</sub>),  
-NHC(O)R<sub>5</sub>, -NHC(O)NHR<sub>5</sub>, -C(O)NHR<sub>5</sub>, -OC(O)R<sub>5</sub>, -OC(O)OR<sub>5</sub>, -SR<sub>5</sub>, -S(O)R<sub>5</sub>, or  
-S(O)<sub>2</sub>R<sub>5</sub>;

R<sub>3</sub> is -H, -halo, -NO<sub>2</sub>, -CN, -OH, -N(R<sub>5</sub>)(R<sub>5</sub>), -O(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>, -C(O)R<sub>5</sub>,  
-C(O)NR<sub>5</sub>R<sub>5</sub>, -C(O)NH(CH<sub>2</sub>)<sub>m</sub>(R<sub>5</sub>), -OCF<sub>3</sub>, -benzyl, -CO<sub>2</sub>CH(R<sub>5</sub>)(R<sub>5</sub>), -(C<sub>1</sub>-C<sub>10</sub>)alkyl,  
35 -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl,  
-(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, -naphthyl, -(C<sub>3</sub>-C<sub>10</sub>)heterocycle,


-CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>, -NHC(O)R<sub>5</sub>, -NHC(O)R<sub>5</sub>, -NHC(O)NHR<sub>5</sub>, -OC(O)(CH<sub>2</sub>)<sub>m</sub>CHR<sub>5</sub>R<sub>5</sub>,  
-CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>CHR<sub>5</sub>R<sub>5</sub>, -OC(O)OR<sub>5</sub>, -SR<sub>5</sub>, -S(O)R<sub>5</sub>, -S(O)<sub>2</sub>R<sub>5</sub>, -S(O)<sub>2</sub>NHR<sub>5</sub>, or



5

R<sub>4</sub> is -CF<sub>3</sub>, -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -benzyl, -adamantyl, -morpholinyl, -pyrrolidyl,  
-pyrroldioxide, -pyrrolidinyldione, -piperidyl, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl,  
-(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl,  
-(C<sub>3</sub>-C<sub>10</sub>)heterocycle, or

10



each R<sub>5</sub> is independently H or R<sub>4</sub>;

15

each R<sub>6</sub> is independently -halo, -NO<sub>2</sub>, -CN, -OH, -CO<sub>2</sub>H, -N(C<sub>1</sub>-  
C<sub>10</sub>)alkyl(C<sub>1</sub>-C<sub>10</sub>)alkyl, -O(C<sub>1</sub>-C<sub>10</sub>)alkyl, -C(O)(C<sub>1</sub>-C<sub>10</sub>)alkyl, -C(O)NH(CH<sub>2</sub>)<sub>m</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl,  
-OCF<sub>3</sub>, -benzyl, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>CH((C<sub>1</sub>-C<sub>10</sub>)alkyl(C<sub>1</sub>-C<sub>10</sub>)alkyl), -C(O)H, -CO<sub>2</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl,  
-(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl,  
-(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, -phenyl,  
20 naphthyl, -(C<sub>3</sub>-C<sub>10</sub>)heterocycle, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>H, -NHC(O)(C<sub>1</sub>-  
C<sub>10</sub>)alkyl, -NHC(O)NH(C<sub>1</sub>-C<sub>10</sub>)alkyl, -OC(O)(C<sub>1</sub>-C<sub>10</sub>)alkyl, -OC(O)O(C<sub>1</sub>-C<sub>10</sub>)alkyl, or  
-SO<sub>2</sub>NH<sub>2</sub>;

20


n is an integer ranging from 0 to 4;

each m is independently an integer ranging from 0 to 8; and

25

each p is independently an integer ranging from 0 to 5.

11. A method for treating an inflammatory bowel disorder in an animal,  
comprising administering to an animal in need thereof an effective amount of a compound  
of formula (Ic):



30

(Ic)


or a pharmaceutically acceptable salt or hydrate thereof, wherein:

R<sub>1</sub> is -H, -CO<sub>2</sub>R<sub>4</sub>; -C(O)R<sub>5</sub>, or -C(O)N(R<sub>5</sub>)(R<sub>5</sub>);




each  $R_2$  is independently -halo, -NO<sub>2</sub>, -CN, -OH, -N(R<sub>5</sub>)(R<sub>5</sub>), -OR<sub>5</sub>, -C(O)R<sub>5</sub>, -OC(O)R<sub>5</sub>, -C(O)NHC(O)R<sub>5</sub>, -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>3</sub>-C<sub>7</sub>)heterocycle, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, phenyl, -naphthyl, -benzyl, -CO<sub>2</sub>R<sub>5</sub>, -C(O)OCH(R<sub>5</sub>)(R<sub>5</sub>),  
 5 -NHC(O)R<sub>5</sub>, -NHC(O)NHR<sub>5</sub>, -C(O)NHR<sub>5</sub>, -OC(O)R<sub>5</sub>, -OC(O)OR<sub>5</sub>, -SR<sub>5</sub>, -S(O)R<sub>5</sub>, or -S(O)<sub>2</sub>R<sub>5</sub>;

$R_3$  is -H, -halo, -NO<sub>2</sub>, -CN, -OH, -N(R<sub>5</sub>)(R<sub>5</sub>), -O(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>, -C(O)R<sub>5</sub>, -C(O)NR<sub>5</sub>R<sub>5</sub>, -C(O)NH(CH<sub>2</sub>)<sub>m</sub>(R<sub>5</sub>), -OCF<sub>3</sub>, -benzyl, -CO<sub>2</sub>CH(R<sub>5</sub>)(R<sub>5</sub>), -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl,  
 10 -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, -naphthyl, -(C<sub>3</sub>-C<sub>10</sub>)heterocycle, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>, -NHC(O)R<sub>5</sub>, -NHC(O)R<sub>5</sub>, -NHC(O)NHR<sub>5</sub>, -OC(O)(CH<sub>2</sub>)<sub>m</sub>CHR<sub>5</sub>R<sub>5</sub>, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>CHR<sub>5</sub>R<sub>5</sub>, -OC(O)OR<sub>5</sub>, -SR<sub>5</sub>, -S(O)R<sub>5</sub>, -S(O)<sub>2</sub>R<sub>5</sub>, -S(O)<sub>2</sub>NHR<sub>5</sub>, or



15  $R_4$  is -CF<sub>3</sub>, -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -benzyl, -adamantyl, -morpholinyl, -pyrrolidyl, -pyrroldioxide, -pyrrolidinyldione, -piperidyl, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>3</sub>-C<sub>10</sub>)heterocycle, or



20 each  $R_5$  is independently H or  $R_4$ ;  
 each  $R_6$  is independently -halo, -NO<sub>2</sub>, -CN, -OH, -CO<sub>2</sub>H, -N(C<sub>1</sub>-C<sub>10</sub>)alkyl, -O(C<sub>1</sub>-C<sub>10</sub>)alkyl, -C(O)(C<sub>1</sub>-C<sub>10</sub>)alkyl, -C(O)NH(CH<sub>2</sub>)<sub>m</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl, -OCF<sub>3</sub>, -benzyl, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>CH((C<sub>1</sub>-C<sub>10</sub>)alkyl(C<sub>1</sub>-C<sub>10</sub>)alkyl), -C(O)H, -CO<sub>2</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, -phenyl, -naphthyl, -(C<sub>3</sub>-C<sub>10</sub>)heterocycle, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>H, -NHC(O)(C<sub>1</sub>-C<sub>10</sub>)alkyl, -NHC(O)NH(C<sub>1</sub>-C<sub>10</sub>)alkyl, -OC(O)(C<sub>1</sub>-C<sub>10</sub>)alkyl, -OC(O)O(C<sub>1</sub>-C<sub>10</sub>)alkyl, or  
 25 -SO<sub>2</sub>NH<sub>2</sub>;

$n$  is an integer ranging from 0 to 4;

each  $m$  is independently an integer ranging from 0 to 8; and


each  $p$  is independently an integer ranging from 0 to 5.

35

12. The method of claim 11, wherein the inflammatory bowel disorder is regional ileitis, colitis, Crohn's disease, or pouchitis.

13. The method of claim 12, wherein the colitis is collagenous or microscopic  
5 colitis, ulcerative colitis, or enterocolitis.

14. A compound of formula (Ib):



(Ib)

10 or a pharmaceutically acceptable salt or hydrate thereof, wherein:

R<sub>1</sub> is -H, -CO<sub>2</sub>R<sub>4</sub>, -C(O)R<sub>5</sub>, or -C(O)N(R<sub>5</sub>)(R<sub>5</sub>);

R<sub>2</sub> is -(C<sub>1</sub>-C<sub>10</sub>)alkyl or -O(C<sub>1</sub>-C<sub>10</sub>)alkyl;

R<sub>4</sub> is -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, phenyl, naphthyl, or benzyl; and

each R<sub>5</sub> is independently -H, -CF<sub>3</sub>, -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -benzyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl,  
15 -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, or -(C<sub>3</sub>-C<sub>10</sub>)heterocycle.

15. The compound or pharmaceutically acceptable salt or hydrate of claim 13,  
wherein R<sub>1</sub> is -H.

20 16. A method for treating an inflammation disease in an animal, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or hydrate of the compound of claim 13.

25 17. The method of claim 15, wherein the inflammation disease is arthritis, psoriasis, gingivitis, colitis, uveitis, diabetes, adult respiratory distress syndrome, autoimmune disease, lupus erythematosus, ileitis, ulcerative colitis, Crohn's disease, asthma, periodontitis, ophthalmitis, endophthalmitis, nephrosis, AIDS-related eurodegeneration, stroke, neurotrauma, Alzheimer's disease, encephalomyelitis, cardio-myopathy, or transplant rejection.

30

18. A method for treating a reperfusion disease in an animal, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or hydrate of the compound of claim 13.

5 19. The method of claim 17, wherein the reperfusion disease is hemorrhagic shock, sepsis, septic shock, myocardial infarction, or stroke.

20. The compound of claim 13, wherein the animal is human.

10 21. A method for inhibiting xanthine oxidase activity in an animal, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or hydrate of the compound of claim 13.

15 22. A method for treating hyperuricemia in an animal, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or hydrate of the compound of claim 13.

23. The method of claim 22, wherein the hyperuricemia is gout.

20 24. A method for treating tumor-lysis syndrome in an animal, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or hydrate of the compound of claim 13.

25 25. A method for treating an inflammatory bowel disorder in an animal, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or hydrate of the compound of claim 13.